Homologous Recombination Deficiency clinical trials at UCSF
1 research study open to eligible people
Homologous recombination deficiency happens when DNA repair is faulty. UCSF is conducting research to check the safety of the drug MOMA-313 for patients with advanced cancer. The trial focuses on understanding how well patients tolerate different doses of the drug.
Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
San Francisco, California and other locations
Our lead scientists for Homologous Recombination Deficiency research studies include Rahul Aggarwal.
Last updated: